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Introduction
Regadenoson is a selective Adenosine-2A receptor ago-
nist and is used for myocardial perfusion imaging.
Dipyridamole causes indirect vasodilation by inhibiting
cellular reuptake of adenosine. The purpose of this
study was to assess whether regadenoson is a better cor-
onary vasodilator than dipyridamole in normal volun-
teers and in patients.
Hypothesis
Regadenoson causes a 25% higher myocardial blood flow
(MBF) than dipyridamole.
Methods
Forty patients with normal coronaries/minimal stenosis
on coronary CT angiography had also undergone vaso-
dilator stress MR (regadenoson n=20, dipyridamole
n=20). Seventeen healthy normal volunteers with Fra-
mingham score less than 1% underwent vasodilator
stress testing with regadenoson and dipyridamole in two
separate studies using a SSFP sequence. Stress imaging
was done 70 seconds post regadenoson injection and 4
minutes after completing the dipyridamole infusion. All
patients and volunteers received aminophylline after
stress imaging. Rest imaging was done 20 minutes later.
MBF in ml/min/g and Myocardial perfusion reserve
(MPR) were quantified using a fully quantitative model
constrained deconvolution (MCD).
Results
Normal volunteers had higher stress MBF (mean ± stan-
dard error) with regadenoson than dipyridamole (3.72±
0.18 vs. 2.90± 0.17, p=0.001) and higher MPR with rega-
denoson (2.75± 0.19 vs. 2.27±0.14, p=.03). In patients,
higher MPR was found with regadenoson (2.45 ± 0.12,
vs. 2.12 ±.10, p=.04). Stress MBF trended higher in
patients with regadenoson than dipyridamole (2.78±
0.14 vs. 2.54± 0.13, p=0.22). No difference in the resting
blood flow between regadenoson and dipyridamole was
found in normal volunteers (1.44± 0.19 vs. 1.31±0.07,
p=.07) and in patients (1.14±0.03 vs. 1.24±0.08, p=.26)
respectively. Figures 1-3.
Conclusions
Regadenoson is a better coronary vasodilator than
Dipyridamole in normal volunteers with higher MBF
and MPR. However in patients, the small sample size in
this study limits the sensitivity to detect differences in
stress perfusion.
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Figure 1 Study design.
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Figure 3 Rest, Stress MBF and MPR in Patients
Figure 2 Rest, Stress MBF and MPR in Normal volunteers
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